Peptide Atlas · Peptide

Survodutide

Survodutide is a dual glucagon and GLP-1 receptor agonist; in a 48-week phase 2 trial in 293 adults with biopsy-confirmed MASH and fibrosis, MASH improved without fibrosis worsening in 43% to 62% on survodutide against 14% on placebo.

emerging

provisional
PubChem 171378821
1 citation
0 discussions
0 followers
BI 456906

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Survodutide improved MASH histology in a 48-week phase 2 trial standing
- resolved
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R, 1404-0043 Trial Investigators
pmid 38847460

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.